Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.
D000328:Adult; D002626:Chemistry, Pharmaceutical; D004334:Drug Administration Schedule; D004715:Endometriosis / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007273:Injections, Intramuscular; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone